Answer
Breastfeeding should be discontinued during treatment with pirtobrutinib (Jaypirca) and for one week after the last dose, because excretion into human milk is unknown and a risk to the child cannot be excluded.
Sources for this answer
- Jaypirca 50mg, 100mg film-coated tabletsEli Lilly and Company Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 4Document updated
Sources checked